HDAC9 and sarcoma: We recently reported that class I histone deacetylase (HDAC) inhibitors induce hyperacetylation within the RNA binding CSD of YB-1 in sarcoma cells [6], thus reducing its binding to cytoprotective mRNAs and downstream effects of their translational activation.